New! Sign up for our free email newsletter.
Science News
from research organizations

Breakthrough antimalarial drug delivery system using mesoporous silica nanoparticles

Date:
March 23, 2018
Source:
Kumamoto University
Summary:
Drug delivery systems (DDSs) are important methods of delivering medicine to affected areas. An international collaborative research group has successfully developed the world's first DDS for antimalarial drugs. The treatment has increased efficiency up to 240 times as much as when antimalarial medicine is taken orally.
Share:
FULL STORY

Drug delivery systems (DDSs) control when and how much drugs are delivered to the body. Numerous DDS studies have been conducted but most have focused on treatments for cancer. New research from Kumamoto University uses a DDS to treat malaria.

The existing treatment for malaria is taken orally and has three main problems: (1) most antimalarial drugs are broken down in the stomach, (2) the drugs have strong side effects, and (3) the medicine stays in the body for only a short time. These issues resulted in malaria treatments that were not particularly effective.

MCM-41 is a porous silica material with a pore size of 2-30 nm. It can incorporate drugs into its pores, which makes it a useful material for DDS applications. A research group headed by Prof. Shinya Hayami from Kumamoto University, Japan believed that MCM-41 could be used as DDS for antimalarial drugs. To test their theory, they created a new DDS by combining the antimalarial drugs Artesunate and Quinine with MCT-41 and performed in vitro and in vivo experiments. They found:

    (1) The release time of the antimalarial medicine became very long, one week or longer, which was an improvement from the standard medication time.

    (2) Compared to ingesting Artesunate or Quinine, the new DDS increased treatment efficiency by 20 and 240 times respectively in animal experiments. (As defined in this study, the therapeutic efficiency is 50% of the effective dose (ED50), and is used as an index of drug strength. The smaller the value of ED50, the greater the action of the drug. In other words, if an effect is obtained with a small amount of a drug, the treatment efficiency is high.)

    (3) MCM-41 itself is non-toxic and inactive. A DDS using MCM-41 is expected to have very weak side effects.

"Using this DDS for antimalarial drugs has introduced a new possibility for highly efficient malaria treatment for the first time," said Professor Shinya Hayami. "We expect that it will be put to practical use in areas where malaria treatment is still necessary. Now, we are planning to develop clinical trials for antimalarial drugs as well as new DDSs for other drugs, like anti-HIV medications."


Story Source:

Materials provided by Kumamoto University. Note: Content may be edited for style and length.


Journal Reference:

  1. Saliu Alao Amolegbe, Yui Hirano, Joseph Oluwatope Adebayo, Olusegun George Ademowo, Elizabeth Abidemi Balogun, Joshua Ayoola Obaleye, Antoniana Ursine Krettli, Chengzhong Yu, Shinya Hayami. Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance. Scientific Reports, 2018; 8 (1) DOI: 10.1038/s41598-018-21351-8

Cite This Page:

Kumamoto University. "Breakthrough antimalarial drug delivery system using mesoporous silica nanoparticles." ScienceDaily. ScienceDaily, 23 March 2018. <www.sciencedaily.com/releases/2018/03/180323104829.htm>.
Kumamoto University. (2018, March 23). Breakthrough antimalarial drug delivery system using mesoporous silica nanoparticles. ScienceDaily. Retrieved November 4, 2024 from www.sciencedaily.com/releases/2018/03/180323104829.htm
Kumamoto University. "Breakthrough antimalarial drug delivery system using mesoporous silica nanoparticles." ScienceDaily. www.sciencedaily.com/releases/2018/03/180323104829.htm (accessed November 4, 2024).

Explore More

from ScienceDaily

RELATED STORIES